Navigation Links
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Date:12/18/2009

SAN DIEGO and TOKYO, Dec. 18 /PRNewswire/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This partnership includes AC220, Ambit's lead clinical-stage investigational drug that entered into a Phase 2 clinical trial earlier this month in relapsed/refractory acute myeloid leukemia (AML), and other undisclosed FLT3 kinase inhibitors. AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a second generation FMS-like tyrosine kinase-3 (FLT3) inhibitor using Ambit's proprietary drug discovery engine, KINOMEscan(TM).

The companies will collaborate to develop AC220 for AML and other indications. The parties will also collaborate on a research and development program for a series of novel FLT3 inhibitors for a variety of oncology and non-oncology indications. The companies will share equally in the responsibilities and expenses for the development of AC220 and any additional products in the U.S. and Europe, while Astellas will have sole responsibility to fund development in all other territories. Under the terms of the agreement, Ambit will receive an up-front cash payment of $40 million and will be eligible to receive pre-commercialization payments of up to $350 million.

Astellas will have sole responsibility for funding and implementing the commercialization of all products, and Ambit will be entitled to post-approval milestone payments upon the achievement of certain sales thresholds, as well as tiered double-digit royalties on net sales. In the U.S., Ambit will also have the option to co-promote AC220 and other products under a profit sharing arrangement where Astellas and Ambit share equally in profits and losses generated from U.S. sales.

"We are pleased
'/>"/>

SOURCE Ambit Biosciences Corporation; Astellas Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
5. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
9. Cell Biosciences Completes Acquisition of Alpha Innotech
10. Neurocrine Biosciences Reports Third Quarter 2009 Results
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... of the KB001-A development program, including an update on ... KB001-A Collaboration Update KaloBios announced that ... regain all rights to KaloBios, KB001-A program. Under this ... 2010 has been terminated. Under that collaboration agreement, Sanofi ...
(Date:7/28/2014)... RESTON, Va. , July 28, 2014 /PRNewswire/ ... management services, announced the Company has been awarded ... Medical Support Command (NEMSCOM) and its Deployable Medical ... to enable medical personnel to provide world-class healthcare ... any operating environment across the globe. The five ...
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... July 6, 2011 Consulting Radiologists, Ltd. (CRL) has ... technology, the first of its kind in Minnesota.  This ... and provide a higher level of patient care with ... techniques without sacrificing image quality. "The addition ...
... R.I., July 6, 2011 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.125 (12.5 cents) per ... 2, 2011 to holders of record on July 22, 2011. ... the Company: CVS Caremark is the largest ...
Cached Medicine Technology:Consulting Radiologists, Ltd. Announces Addition of a Low Dose Advanced Computed Tomography (CT) System 2
(Date:7/28/2014)... 2014 Camp Soaring Eagle today ... property in Cornville, AZ. The nonprofit organization, founded ... the opportunity to attend medically supervised camps at ... organization offers a variety of programs to Arizona ... life threatening illnesses including: Illness Specific Camping Weekends, ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... are at risk of contracting meningitis because of specific ... to updated recommendations from the largest pediatrician group in ... the potentially deadly infection should continue for adolescents and ... In its first statement on meningococcal vaccines since 2011, ...
(Date:7/28/2014)... not divide unless there is enough oxygen present to ... cell types circumvent this rule. Researchers at The Johns ... the cells, warning signals, enabling cancers to continue to ... process, the researchers found that lysosomes the cell,s ... They also uncovered new evidence that certain drugs can ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Cell's recycling center implicated in division decisions 2
... is no exception. To all those who wish kick the ... mind-blowing news. Smokers // world over are swearing ... laser therapy, likened to a modern form of acupuncture has ... that of most other smoking cessation programmes. For the first ...
... the past have been recommended to take up a screening program ... cancer if any, at an early stage. // This would enable ... ,The need for the screening is further stressed in ... those of you who have still taken smoking very lightly, we ...
... University of California have now established a very strong ... renal disease. So if you are thinking over losing weight, ... to lose. // ,"There are more and ... much that kidney failure can be a consequence of obesity," ...
... Padua have found that the some complications // ... immediately after birth) could play a major role in ... anorexia nervosa and bulimia nervosa. ,Previous studies ... a complex interplay of genetic and environmental factors. Results ...
... founder president of the National Obesity Forum has resigned ... founding the national anti-obesity program at a time when ... obesity. Campbell’s resignation from the forum has taken many ... in the forum against him as they threatened him ...
... The American Society of Clinical Oncology has chosen 11 ... cancer for the year 2005. Prominent// among them is ... recurrence of HER-2-positive early-stage breast cancer. ... early-stage lung cancer is successful if chemotherapy is given ...
Cached Medicine News:Health News:Zap the butt (cigarette) with Laser Therapy 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2Health News:Complications During Delivery Related To Eating Disorders 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: